Details of the Drug Reposition

General Information of This Drug (ID: DM7YII9)

• Drug Name: Dazodalibep (DM7YII9)
• Synonyms: VIB4920

Information on Drug Reposition of This Drug

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sjogren syndrome	DISUBX7H	4A43.20	Phase 2	[1]
Rheumatoid arthritis	DISTSB4J	FA20	Phase 2	[2]
Kidney transplant rejection	DISJ1FYS	NE84	Phase 2	[3]

References

• [1] ClinicalTrials.gov (NCT04129164) A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sj?gren's Syndrome (SS). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04163991) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04046549) A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant. U.S.National Institutes of Health.